HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): John A. Hawkins Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shaddy, R. E. Articles by Hawkins, J. A. Search for Related Content PubMed PubMed Citation Articles by Shaddy, R. E. Articles by Hawkins, J. A. Related Collections Congenital - cyanotic Valve disease Related Article

Ann Thorac Surg 2001;71:43-47
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Prospective randomized trial of azathioprine in cryopreserved valved allografts in children

^a Department of Pediatrics, Primary Children’s Medical Center and University of Utah, Salt Lake City, Utah, USA
^b Department of Surgery, Primary Children’s Medical Center and University of Utah, Salt Lake City, Utah, USA
^c Department of Pathology, Primary Children’s Medical Center and University of Utah, Salt Lake City, Utah, USA

Accepted for publication July 10, 2000.

Address reprint requests to Dr Shaddy, Cardiology, Primary Children’s Medical Center, Suite 1500, 100 North Medical Dr, Salt Lake City, Utah 84113
e-mail: pcrshadd{at}ihc.com

Background. The purpose of this study was to prospectively assess the effects of azathioprine on the humoral immune response to HLA alloantigens and allograft function in children receiving cryopreserved valved allografts.

Methods. We randomized 13 children to receive azathioprine or not to receive azathioprine (controls) after receiving a cryopreserved valved allograft. Azathioprine patients received intraoperatively 4 mg/kg of azathioprine and 2.0 ± 0.5 mg/kg once daily for 3 months after operation. Panel reactive antibodies against HLA class I and class II alloantigens were measured before, 1 month, and 3 months after operation.

Results. Panel reactive antibodies were not significantly different between the azathioprine and control groups before (0.0% ± 0% versus 1.6% ± 1%), 1 month (59% ± 17% versus 71% ± 12%), or 3 months (84% ± 15% versus 96% ± 1.3%) after operation. There were no differences in degree of allograft valve stenosis between azathioprine (31.5 ± 26 mm Hg, 13.4 ± 7 months postoperatively) and control groups (25.4 ± 11 mm Hg, 17.2 ± 10 months postoperatively) or allograft valve insufficiency.

Conclusions. Azathioprine does not significantly decrease the immune response to HLA alloantigens or affect the function of cryopreserved valved allografts used in children to repair congenital heart defects.

Related Article

Invited commentary

Richard A. Hopkins, Diane Hoffman–Kim, and Mary S. Maish
Ann. Thorac. Surg. 2001 71: 47-48. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. O. Bohm, C. A. Botha, A. Horke, W. Hemmer, D. Roser, G. Blumenstock, F. Uhlemann, and J.-G. Rein Is the Ross operation still an acceptable option in children and adolescents? Ann. Thorac. Surg., September 1, 2006; 82(3): 940 - 947. [Abstract] [Full Text] [PDF]

				F. D. Affonso da Costa, P. M. Dohmen, D. Duarte, C. von Glenn, S. V. Lopes, H. H. Filho, M. B. Affonso da Costa, and W. Konertz Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 572 - 578. [Abstract] [Full Text] [PDF]

				D. K. Hooper, J. A. Hawkins, T. C. Fuller, T. Profaizer, and R. E. Shaddy Panel-Reactive Antibodies Late After Allograft Implantation in Children Ann. Thorac. Surg., February 1, 2005; 79(2): 641 - 644. [Abstract] [Full Text] [PDF]

				R. E. Shaddy, T. C. Fuller, J. B. Anderson, L. M. Lambert, M. K. Brinkman, T. Profaizer, and J. A. Hawkins Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation Ann. Thorac. Surg., May 1, 2004; 77(5): 1734 - 1739. [Abstract] [Full Text] [PDF]

				J. T. Christenson, D. Vala, J. Sierra, M. Beghetti, and A. Kalangos Blood group incompatibility and accelerated homograft fibrocalcifications J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 242 - 250. [Abstract] [Full Text] [PDF]

				J. A. Hawkins, N. D. Hillman, L. M. Lambert, J. Jones, G. B. Di Russo, T. Profaizer, T. C. Fuller, L. L. Minich, R. V. Williams, and R. E. Shaddy Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 247 - 252. [Abstract] [Full Text] [PDF]

				S. Chauvaud, T. Waldmann, N. d'Attellis, P. Bruneval, C. Acar, J. Gerota, M. Jarraya, and A. Carpentier Homograft replacement of the mitral valve in young recipients: mid-term results Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 560 - 566. [Abstract] [Full Text] [PDF]

				R. E. Shaddy and J. A. Hawkins Immunology and failure of valved allografts in children Ann. Thorac. Surg., October 1, 2002; 74(4): 1271 - 1275. [Abstract] [Full Text] [PDF]

				W. J. Wells, H. Arroyo Jr, R. M. Bremner, J. Wood, and V. A. Starnes Homograft conduit failure in infants is not due to somatic outgrowth J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 88 - 96. [Abstract] [Full Text] [PDF]